DTIL supply chain intelligence for Precision BioSciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Precision BioSciences, Inc. (DTIL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MXCT | MaxCyte, Inc. | 85% | Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial mil… |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demo… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU… |
| CLLS | Cellectis S.A. | 72% | Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, … |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices … |
| FISI | Financial Institutions, Inc. | 72% | Reciprocal relationship from FISI graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from FISI graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from FISI g… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX grap… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteris… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX g… |
| IECURE-INC | IECURE-INC | 60% | The Company adjusts the carrying value of the iECURE, Inc. equity to fair value each reporting period |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TG-THERAPEUTICS | TG-THERAPEUTICS | 90% | Under the TG License Agreement, the Company received an upfront cash payment of $ 10.0 million |
| AGRICULTURE-INDUSTRY-COLLABORATION-PARTNER | AGRICULTURE-INDUSTRY-COLLABORATION-PARTNER | 80% | The Company recognized $ 4.0 million in revenue under a legacy ARCUS gene editing research and license agreement milestone from an agriculture industry collaboration partner |
| SERVIER | SERVIER | 80% | The Program Purchase Agreement requires the Company to make certain payments to Servier based on the achievement of regulatory and commercial milestones for each product |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU g… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the dem… |
| CLLS | Cellectis S.A. | 72% | Reciprocal relationship from CLLS graph: Reciprocal relationship from DTIL graph: es pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulato… |
| CLLS | Cellectis S.A. | 72% | es pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for m… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| FISI | Financial Institutions, Inc. | 72% | Reciprocal relationship from FISI graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from FISI graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from FISI g… |
| FISI | Financial Institutions, Inc. | 72% | of our future net losses will depend, in part, on the amount and growth rate of our expenses and our ability to generate revenues. All of our current or future product candidates will require substan… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing … |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT g… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations.… |
| NOVARTIS-PHARMA-AG | NOVARTIS-PHARMA-AG | 70% | The Company recognized revenue under the Novartis Agreement of less than $ 0.1 million |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | Interest income was $1.0 million during the three months ended March 31, 2026 compared to $1.3 million during the three months ended March 31, 2025. The decrease of approximately $0.3 million was pri… |
| ELO-LIFE-SYSTEMS-INC | ELO-LIFE-SYSTEMS-INC | 62% | cal study materials; • license payments made for intellectual property used in research and development activities; and • facility-related expenses, which include direct depreciation costs and expens… |
| IMUGENE-LIMITED | IMUGENE-LIMITED | 62% | cal study materials; • license payments made for intellectual property used in research and development activities; and • facility-related expenses, which include direct depreciation costs and expens… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DTIL-DEBT-9166 | Warrants outstanding: 11129000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| DTIL-DEBT-9167 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| DTIL-DEBT | Debt stack $22.3M | 90% | Market cache reports total debt of $22.3M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DTIL-OWNER-OCTAGON-CAPITAL-ADVISORS-LP | Octagon Capital Advisors LP | 90% | 13F overlay lists Octagon Capital Advisors LP as top holder; 78 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CHYM | Chime Financial, Inc. | 100.00 | 2 | |
| BSAC | Banco Santander-Chile | 100.00 | 2 | |
| FNWB | First Northwest Bancorp | 100.00 | 2 | |
| ARMK | Aramark | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| BRBS | Blue Ridge Bankshares, Inc. | 100.00 | 2 | |
| BRBI | BRBI BR Partners S.A. | 100.00 | 2 | |
| ENLT | Enlight Renewable Energy Ltd | 100.00 | 2 | |
| CELUW | Celularity Inc | 100.00 | 1 | ['customer', 'supplier'] |
| ARM | Arm Holdings plc | 100.00 | 2 | |
| BLX | Banco Latinoamericano de Comercio Exterior, S. A. | 100.00 | 2 | |
| BMA | Banco Macro S.A. | 100.00 | 2 | |
| CNF | CNFinance Holdings Limited | 100.00 | 2 | |
| AVAL | Grupo Aval Acciones y Valores S.A. | 100.00 | 2 | |
| BSBR | Banco Santander (Brasil) S.A. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BTTC | Black Titan Corporation | 100.00 | 2 | |
| BBAR | Banco BBVA Argentina S.A. | 100.00 | 2 | |
| VRNO | Verano Holdings Corp. | 100.00 | 2 | |
| BCH | Banco de Chile | 100.00 | 2 |